Afamelanotide

Phase 2UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Xeroderma Pigmentosum

Conditions

Xeroderma Pigmentosum

Trial Timeline

Mar 28, 2022 → Dec 1, 2024

NCT ID

NCT05370235

About Afamelanotide

Afamelanotide is a phase 2 stage product being developed by Clinuvel Pharmaceuticals for Xeroderma Pigmentosum. The current trial status is unknown. This product is registered under clinical trial identifier NCT05370235. Target conditions include Xeroderma Pigmentosum.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05210582	Phase 2	UNKNOWN	Oct 11, 2022	Aug 1, 2023	Vitiligo
NCT05370235	Phase 2	UNKNOWN	Mar 28, 2022	Dec 1, 2024	Xeroderma Pigmentosum
NCT05368857	Phase 1	Completed	Jan 19, 2022	Feb 1, 2023	Afamelanotide Evaluated as Skin DNA Repair Therapy in Healthy Volunteers
NCT05159752	Phase 2	UNKNOWN	Oct 19, 2021	Oct 1, 2024	Xeroderma Pigmentosum
NCT04962503	Phase 2	Completed	Jun 3, 2021	Feb 4, 2022	Arterial Ischemic Stroke
NCT01382589	Phase 2	Completed	Sep 1, 2011	Dec 1, 2012	Vitiligo
NCT04578496	Phase 3	Completed	Jul 11, 2011	Feb 27, 2014	Erythropoietic Protoporphyria
NCT01430195	Phase 1	Completed	Jun 1, 2011	Nov 1, 2012	Vitiligo
NCT04943159	Phase 2	Completed	Aug 24, 2010	Mar 8, 2011	Acne Vulgaris
NCT00859534	Phase 2	Completed	Dec 1, 2008	Jul 1, 2009	Solar Urticaria

Competing Products

1 competing product in Xeroderma Pigmentosum

See all competitors

Product	Company	Stage	Hype Score
Afamelanotide	Clinuvel Pharmaceuticals	Phase 2	25